Angiosarcoma in the breast: a population-based cohort from Sweden
British Journal of Surgery · 2023
DOI: 10.1093/bjs/znad290 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Surgery, 2023. Verfasst von Susanne Olander und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Sunderby Hospital, Luleå, Sweden. Hauptthemen laut MEDLINE: Hemangiosarcoma, Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Vasternorrland County Council, Vasterbotten County Council, Swedish Breast Cancer Society.
Abstract (Originalsprache)
Background
Breast angiosarcoma is a rare disease mostly observed in breast cancer (BC) patients who have previously received radiotherapy (RT). Little is known about angiosarcoma aetiology, management, and outcome. The study aim was to estimate risk and to characterize breast angiosarcoma in a Swedish population-based cohort.
Methods
The Swedish Cancer Registry was searched for breast angiosarcoma between 1992 and 2018 in three Swedish healthcare regions (population 5.5 million). Information on previous BC, RT, management, and outcome were retrieved from medical records.
Results
Overall, 49 angiosarcomas located in the breast, chest wall, or axilla were identified, 8 primary and 41 secondary to BC treatment. Median age was 51 and 73 years, respectively. The minimum latency period of secondary angiosarcoma after a BC diagnosis was 4 years (range 4–21 years). The cumulative incidence of angiosarcoma after breast RT increased continuously, reaching 1.4‰ after 20 years. Among 44 women with angiosarcoma treated by surgery, 29 developed subsequent local recurrence. Median recurrence-free survival was 3.4 and 1.8 years for primary and secondary angiosarcoma, respectively. The 5-year overall survival probability for the whole cohort was 50 per cent (95 per cent c.i., 21 per cent–100 per cent) for primary breast angiosarcoma and 35 per cent (95 per cent c.i., 23 per cent–54 per cent) for secondary angiosarcoma.
Conclusion
Breast angiosarcoma is a rare disease strongly associated with a history of previous BC RT. Overall survival is poor with high rates of local recurrences and distant metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Sunderby Hospital, Luleå, Sweden.
- Department of Surgery and Perioperative sciences/Surgery, Umeå University, Umeå, Sweden.
- Department of Oncology, Sundsvall Hospital, Sundsvall, Sweden.
- Regional Cancer Center, Uppsala University, Uppsala, Sweden.
- Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
- Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, University Hospital, Uppsala, Sweden.
ORCID-Profile: Fredrik Wärnberg, Malin Sund, Charlotta Wadsten
Förderung
- Vasternorrland County Council
- Vasterbotten County Council
- Swedish Breast Cancer Society
- Percy Falk Foundation
- Visare Norr
Zitieren
APA
Olander, S., Wennstig, A. K., Garmo, H., Holmberg, L., Nilsson, G., Blomqvist, C., Karlsson, F., Wickberg, Å., Wärnberg, F., Sund, M., & Wadsten, C. (2023). Angiosarcoma in the breast: a population-based cohort from Sweden. British Journal of Surgery. https://doi.org/10.1093/bjs/znad290
Vancouver
Olander S, Wennstig AK, Garmo H, Holmberg L, Nilsson G, Blomqvist C, et al. Angiosarcoma in the breast: a population-based cohort from Sweden. British Journal of Surgery. 2023. doi:10.1093/bjs/znad290
BibTeX
@article{Olander2023,
author = {Olander, Susanne and Wennstig, Anna-Karin and Garmo, Hans and Holmberg, Lars and Nilsson, Greger and Blomqvist, Carl and Karlsson, Fredrik and Wickberg, Åsa and Wärnberg, Fredrik and Sund, Malin and Wadsten, Charlotta},
title = {Angiosarcoma in the breast: a population-based cohort from Sweden},
journal = {British Journal of Surgery},
year = {2023},
doi = {10.1093/bjs/znad290}
}
EUVIMED